We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+10.81%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$4.15B
AUM Growth
+$599M
Cap. Flow
+$538M
Cap. Flow %
12.94%
Top 10 Hldgs %
45.29%
Holding
99
New
22
Increased
37
Reduced
6
Closed
9

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$62M
2
IMVT icon
Immunovant
IMVT
+$53.9M
3
CYTK icon
Cytokinetics
CYTK
+$46.8M
4
LONA
LeonaBio Inc
LONA
+$44.6M
5
GH icon
Guardant Health
GH
+$42.9M

Top Sells

Rank Stock Value
1
WVE icon
Wave Life Sciences
WVE
+$24.9M
2
QTTB icon
Q32 Bio
QTTB
+$22.8M
3
STAA icon
STAAR Surgical
STAA
+$19M
4
NEO icon
NeoGenomics
NEO
+$13.8M
5
RPTX
Repare Therapeutics
RPTX
+$6.98M

Sector Composition

Rank Sector Weight
1 Healthcare 92.6%
2 Materials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
1
Rocket Pharmaceuticals
RCKT
$355M
$384M 9.25%
16,812,491
– –
IMVT icon
2
Immunovant
IMVT
$8.23B
$264M 6.36%
7,510,412
+1,793,230
+31% +$53.9M
ALNY icon
3
Alnylam Pharmaceuticals
ALNY
$37.2B
$245M 5.9%
1,681,645
– –
PTCT icon
4
PTC Therapeutics
PTCT
$6.29B
$187M 4.49%
3,993,286
+30,166
+0.8% +$1.49M
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$182M 4.38%
1,096,005
+8,279
+0.8% +$1.13M
DRNA
6
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$130M 3.13%
7,227,413
+74,495
+1% +$1.54M
MYOK
7
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$128M 3.08%
936,931
– –
NTRA icon
8
Natera
NTRA
$37B
$124M 2.98%
1,710,769
+181,641
+12% +$10.3M
AXSM icon
9
Axsome Therapeutics
AXSM
$12.3B
$119M 2.87%
1,670,938
+12,622
+0.8% +$984K
STOK icon
10
Stoke Therapeutics
STOK
$1.83B
$119M 2.86%
3,544,248
– –
RNAM
11
DELISTED
Avidity Biosciences
RNAM
$110M 2.65%
3,995,000
– –
MASI
12
DELISTED
Masimo
MASI
$106M 2.56%
450,390
+61,614
+16% +$13.8M
CERN
13
DELISTED
Cerner Corp
CERN
$101M 2.42%
1,392,049
+209,640
+18% +$14.9M
AXNX
14
DELISTED
Axonics, Inc. Common Stock
AXNX
$96.2M 2.32%
1,883,864
+607
+0% +$25.3K
BAX icon
15
Baxter International
BAX
$12.1B
$86.6M 2.09%
1,077,268
+107,898
+11% +$9.08M
TXG icon
16
10x Genomics
TXG
$5.83B
$82.4M 1.98%
660,933
+24,841
+4% +$2.61M
ADVM
17
DELISTED
Adverum Biotechnologies
ADVM
$74.5M 1.79%
723,476
+44,473
+7% +$6.66M
VCEL icon
18
Vericel Corp
VCEL
$2.31B
$71.4M 1.72%
3,850,851
+504
+0% +$8.34K
TNDM icon
19
Tandem Diabetes Care
TNDM
$1.18B
$68.5M 1.65%
603,481
+4,558
+0.8% +$479K
PTGX icon
20
Protagonist Therapeutics
PTGX
$8.72B
$66.6M 1.6%
3,408,961
+25,753
+0.8% +$483K
RLMD icon
21
Relmada Therapeutics
RLMD
$546M
$56.9M 1.37%
1,511,337
+30,485
+2% +$1.18M
ILMN icon
22
Illumina
ILMN
$28.7B
$54.1M 1.3%
+179,900
New +$62M
GH icon
23
Guardant Health
GH
$19.3B
$52.5M 1.26%
+469,498
New +$42.9M
AGEN
24
Agenus
AGEN
$255M
$51.5M 1.24%
655,455
– –
TBIO
25
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$51M 1.23%
3,745,286
+28,292
+0.8% +$436K
1
2 3 4

Similar funds

LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $9.92B AUM 21.52% 1-Year Est. Return

RTW Investments's Q3 2020 Portfolio in Review

As of Q3 2020, RTW Investments held 99 positions worth $4.15B, up 17% from $3.55B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RTW Investments deployed $538M of net new capital in Q3 2020, opening 22 new positions and adding to 37 existing holdings. Its largest new stake was Illumina: 179,900 shares worth $54.1M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Q32 Bio, an estimated $22.8M trimmed.

  • RTW Investments's largest Q3 2020 buy was Illumina: 179,900 shares worth $54.1M.
  • RTW Investments added most to Immunovant in Q3 2020, an estimated $53.9M increase.
  • RTW Investments's biggest Q3 2020 reduction was Q32 Bio, cutting an estimated $22.8M.
  • RTW Investments fully exited Wave Life Sciences in Q3 2020, selling an estimated $24.9M.
  • RTW Investments's ten largest holdings make up 45% of its $4.15B portfolio in Q3 2020.
  • RTW Investments opened 22 new positions and closed 9 in Q3 2020.
  • RTW Investments's portfolio value rose 17% quarter-over-quarter to $4.15B.

Based on RTW Investments's 13F filing for Q3 2020, filed 16 Nov 2020.